Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eculizumab - Alexion Pharmaceuticals

Drug Profile

Eculizumab - Alexion Pharmaceuticals

Alternative Names: 5G1-1; 5G1.1; Anti-C5 monoclonal antibody 5G1-1; h5G1.1; Monoclonal antibody 5G1-1; Soliris

Latest Information Update: 06 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexion Pharmaceuticals
  • Developer Alexion Pharmaceuticals; Brigham and Womens Hospital; Chiba University; Handok Inc
  • Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Delayed graft function; Neuromyelitis optica; Transplant rejection; Haemolytic uraemic syndrome; Myasthenia gravis; Dermatomyositis; Membranous glomerulonephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemolytic uraemic syndrome; Myasthenia gravis; Neuromyelitis optica; Paroxysmal nocturnal haemoglobinuria
  • Phase III Delayed graft function
  • Phase II Guillain-Barre syndrome; Renal transplant rejection
  • Clinical Phase Unknown COVID 2019 infections
  • No development reported Antiphospholipid syndrome; Heart transplant rejection
  • Discontinued Adult respiratory distress syndrome; Age-related macular degeneration; Allergic asthma; Autoimmune haemolytic anaemia; Bullous pemphigoid; Dermatomyositis; Glomerulonephritis; Idiopathic thrombocytopenic purpura; Lupus nephritis; Membranous glomerulonephritis; Motor neuron disease; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 30 Jul 2020 Alexion Pharmaceuticals plans a phase III trial for Guillain-Barre syndrome in Japan (IV) in 2021
  • 01 Jun 2020 Eculizumab receives SAKIGAKE designation for Gullain Barre Syndrome in Japan
  • 06 May 2020 Alexion Pharmaceuticals plans a phase II/III trial for Neuromyelitis optica (In children, In adolescents) in Japan (IV) in the mid 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top